Can’t Win Them All: Two Merck Oncology Trials Fail
Stalwarts Lynparza And Keytruda Miss Their Mark
Executive Summary
The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.
You may also be interested in...
AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.
AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data
The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.